Paradise system is catheter-based system designed to denervate the renal nerves with ultrasound energy.


Hypertension causes increased cardiovascular morbidity and mortality. (Credit: Gerald Oswald from Pixabay)

ReCor Medical has secured Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its Paradise system to treat uncontrolled hypertension.

The Paradise Ultrasound Renal Denervation System is designed to treat hypertensive patients who are inadequately responsive to anti-hypertensive medications.

It is a catheter-based system designed to denervate the renal nerves with ultrasound energy.

Hypertension, which is said to one of the major contributors to disease burden worldwide, causes increased cardiovascular morbidity and mortality.

In the US, the Paradise system is an investigational device and has been studied in RADIANCE-SOLO and RADIANCE-TRIO, the two FDA IDE clinical trials.

Currently, ReCor is conducting an FDA IDE pivotal study (RADIANCE-II HTN) of the system in patients with uncontrolled hypertension.

ReCor regulatory and medical affairs vice president Leslie Coleman said: “ReCor is pleased that the FDA granted the Breakthrough Designation to the Paradise System.

“ReCor believes that Paradise is truly innovative and has the potential to provide an important and innovative therapy option to hypertensive patients worldwide.”

ReCor, a wholly-owned subsidiary of Otsuka Medical Devices, has also announced today that its Paradise system showed positive results in the RADIANCE-HTN TRIO (TRIO) study.

The TRIO trial evaluated the efficacy and safety of the system in reducing blood pressure in hypertensive patients.

ReCor said that the trial met its primary efficacy endpoint of a greater reduction in daytime blood pressure (Daytime ABPM) in the patients. The reduction was observed between baseline and 2-month follow-up with the Paradise system as compared with the sham procedure.

ReCor Medical president and CEO Andrew Weiss said: “ReCor is very pleased with the TRIO outcomes, which demonstrate a clear Paradise treatment effect versus sham.

“ReCor believes that TRIO is a unique randomized, sham-controlled study in hypertension given the use of single pill triple medication to set a common baseline medication level in all study subjects, thus helping to establish that the Paradise RDN procedure can provide an additional clinical benefit to patients who are resistant to anti-hypertensive medications.”